Novo Nordisk exits R&D in inflammatory disorders
03 September 2014 | News | By BioSpectrum Bureau
Novo Nordisk exits R&D in inflammatory disorders
On September 2, 2014, Novo Nordisk officially announced its decision to discontinue all its R&D activities within inflammatory disorders.
The company said that it will increase its focus and efforts more within diabetes prevention and treatment, obesity and diabetes complications.
